PCSK9 and venous thromboembolism: Glucocorticoid treatment has been associated with an increased risk of cardiovascular events,21 including venous thromboembolism.13 28 In contrast, a notable reduction in venous thromboembolism has been observed with PCSK9 inhibitor treatment,29 suggesting PCSK9’s potential role in the heightened risk of venous thromboembolism with glucocorticoid treatment.